围产期心肌病：外泌体发挥作用吗？

Peripartum Cardiomyopathy: Do Exosomes Play a Role?

作者信息

Gu Huanyu, Dai Qiying, Liu Zhuyuan, Wang Hongbao, Yao Jianhua, Zhou Lei

机构信息

Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.

Metrowest Medical Center, Framingham, MA, 01702, USA.

出版信息

Adv Exp Med Biol. 2017;998:139-149. doi: 10.1007/978-981-10-4397-0_9.

DOI:10.1007/978-981-10-4397-0_9

PMID:28936737

Abstract

Peripartum cardiomyopathy (PPCM) refers to irreversible cardiomyocyte damage that occurs during the last month of pregnancy, or within 5 months after giving birth. It is characterized by systolic heart failure. This life-threatening condition is relatively uncommon, but the incidence has been climbing up. Because of its high mortality, it is crucial for physicians to have high suspicious for the disease. Studies have been done to search into specific lab test and treatment for PPCM. Therapies like anti-viral, anti-inflammatory and immunosuppression regimen have been explored. New regimen like exosomes has also been explored and revealed promising effects.

摘要

围产期心肌病（PPCM）是指在妊娠最后一个月或分娩后5个月内发生的不可逆心肌细胞损伤。其特征为收缩性心力衰竭。这种危及生命的疾病相对不常见，但发病率一直在上升。由于其高死亡率，医生对该疾病保持高度怀疑至关重要。已经开展了研究以探寻PPCM的特定实验室检查和治疗方法。抗病毒、抗炎和免疫抑制方案等治疗方法已被探索。外泌体等新方案也已被探索并显示出有前景的效果。